These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6474409)

  • 1. Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis.
    Hafter R; Klaubert W; Gollwitzer R; von Hugo R; Graeff H
    Thromb Res; 1984 Jul; 35(1):53-64. PubMed ID: 6474409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Markerfunction of crosslinked fibrin derivatives in ascitic fluid from patients with ovarian cancer: a comparison with ascitic fluid in liver cirrhosis].
    Graeff H; Klaubert W; Klaubert E; Gollwitzer R; von Hugo R; Hafter R
    Geburtshilfe Frauenheilkd; 1983 Jun; 43 Suppl 1():42-6. PubMed ID: 6555132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer.
    Paternoster D; Maggino T; Valente S; Paternoster A; Pengo V; Marchesoni D
    Clin Exp Obstet Gynecol; 1981; 8(2):64-5. PubMed ID: 7199979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer.
    Paternoster D; Maggino T; Valente S; Pengo V; Marchesoni D
    Eur J Gynaecol Oncol; 1981; 2(3):127-8. PubMed ID: 7347682
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of fibrin(ogen) fragments in gingival crevicular fluid.
    Talonpoika J
    Scand J Dent Res; 1991 Feb; 99(1):40-3. PubMed ID: 2047751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites.
    Thaler J; Lisman T; Quehenberger P; Hell L; Schwabl P; Scheiner B; Bucsics T; Nieuwland R; Ay C; Trauner M; Pabinger I; Reiberger T; Mandorfer M
    Thromb Haemost; 2022 Mar; 122(3):353-362. PubMed ID: 34020489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of crosslinked fibrin derivatives in plasma and ascitic fluid with monoclonal antibodies against D dimer using EIA and latex test.
    Hafter R; Schröck R; von Hugo R; Graeff H
    Scand J Clin Lab Invest Suppl; 1985; 178():137-44. PubMed ID: 3867114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma.
    Wilhelm O; Hafter R; Coppenrath E; Pflanz MA; Schmitt M; Babic R; Linke R; Gössner W; Graeff H
    Cancer Res; 1988 Jun; 48(12):3507-14. PubMed ID: 3130986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinolysis in ascitic fluid: isolation and characterization of fibrin derivatives, their interaction with albumin.
    Wilhelm O; Hafter R; Graeff H
    Thromb Res; 1987 Sep; 47(6):673-81. PubMed ID: 3686482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.
    Lane DA; Preston FE; VanRoss ME; Kakkar VV
    Br J Haematol; 1978 Dec; 40(4):609-15. PubMed ID: 365218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal coagulation in chronic liver disease ascites.
    Hoefs J; Barnes T; Halle P
    Dig Dis Sci; 1981 Jun; 26(6):518-22. PubMed ID: 7238271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property.
    Jandu N; Richardson M; Singh G; Hirte H; Hatton MW
    Int J Gynecol Cancer; 2006; 16(4):1536-44. PubMed ID: 16884362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and comparison of hemocoagulation parameters both in serum and in ascites from patients with gynecologic malignancies.
    Varcaccio-Garofalo G; Selvaggi L; Capozza G; Orlando E; Ferreri R; Restaino A
    Eur J Gynaecol Oncol; 1982; 3(2):113-4. PubMed ID: 7166171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease.
    Agarwal S; Joyner KA; Swaim MW
    Am J Gastroenterol; 2000 Nov; 95(11):3218-24. PubMed ID: 11095345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique.
    Connaghan DG; Francis CW; Lane DA; Marder VJ
    Blood; 1985 Mar; 65(3):589-97. PubMed ID: 3971042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure.
    Francis CW; Marder VJ; Barlow GH
    J Clin Invest; 1980 Nov; 66(5):1033-43. PubMed ID: 6448866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile constituents in ascitic fluid.
    Hedenborg G; Jönsson G; Norman A; Wisén O
    Scand J Clin Lab Invest; 1988 Oct; 48(6):543-52. PubMed ID: 3217757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemostatic Findings in Ascitic Fluid: A Cross-Sectional Study in 70 Dogs.
    Zoia A; Drigo M; Piek CJ; Simioni P; Caldin M
    J Vet Intern Med; 2017 Jan; 31(1):43-50. PubMed ID: 27862300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.
    Wilhelm O; Hafter R; Henschen A; Schmitt M; Graeff H
    Blood; 1990 Apr; 75(8):1673-8. PubMed ID: 2139349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A DIC-like picture on plasma and ascitic fluid of cirrhotic patients.
    Patrassi GM; Sartori MT; Sgarabotto D; Sturniolo G; Boeri G; Girolami A
    Res Exp Med (Berl); 1988; 188(5):351-6. PubMed ID: 3147501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.